Interleukin-4 Receptor alpha Antagonist [EPC] - N0000193342

Pharmacologic Class Information

Pharmacologic Code N0000193342
Pharmacologic Name Interleukin-4 Receptor alpha Antagonist
Pharmacologic Uses
  • interleukin-4 receptor alpha antagonist
Pharmacologic Concept Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions:
  • A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication.
  • A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

NDC Products with Interleukin-4 Receptor alpha Antagonist

The table contains 5 products whose active ingredient are classified under the same pharmacologic class Interleukin-4 Receptor alpha Antagonist [EPC].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
0024-5911Dupixent Non-Proprietary Name: DupilumabInjection, SolutionSubcutaneousSanofi-aventis U.s. LlcACTIVE
0024-5914Dupixent Non-Proprietary Name: DupilumabInjection, SolutionSubcutaneousSanofi-aventis U.s. LlcACTIVE
0024-5915Dupixent Non-Proprietary Name: DupilumabInjection, SolutionSubcutaneousSanofi-aventis U.s. LlcACTIVE
0024-5918Dupixent Non-Proprietary Name: DupilumabInjection, SolutionSubcutaneousSanofi-aventis U.s. LlcACTIVE
0024-5919Dupixent Non-Proprietary Name: DupilumabInjection, SolutionSubcutaneousSanofi-aventis U.s. LlcACTIVE